Welcome to DukeHealth.org.
Skip over navigation
  • Home
  • Services
  • Locations
  • Physicians
  • Patient and Visitor Info
  • Clinical Trials
  • Event Calendar
  • Health Library
  • About Duke Medicine

Quick Links

  • Appointments
  • HealthView Patient Login
  • Quality and Safety
Home > Physicians > Lanasa, Mark C.
Jumbo Large Regular Text:
Print E-mail
Physicians

Mark C. Lanasa, MD, PhD

Related Content

Services

  • Duke Center for Chronic Lymphocytic Leukemia
  • Hematologic Malignancies Program

Share

Mark C. Lanasa, MD, PhD

Department / Division
Medicine / Medicine - Oncology

Address
DUMC 3872
Durham, NC 27710

Appointment Telephone
919-684-8964

Office Telephone
919-684-8964

Fax Telephone
919-684-5325

Training
  • MD, University of Pittsburgh School of Medicine (Pennsylvania), 2002

Residency
  • Internal Medicine, Duke University Medical Center, 2002-2005

Fellowship
  • Hematology/Medical Oncology, Duke University Medical Center, 2005-2008

Other Training
  • PhD, Biochemistry and Molecular Genetics, University of Pittsburgh (Pennsylvania), 2000

Clinical Interests
Chronic lymphocytic leukemia, small lymphocytic lymphoma, B-cell lymphoproliferative disorders

Research Interests
Chronic Lymphocytic Leukemia, B Cell Lymphoproliferative Disorders

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

  • Genentech, Inc (Roche Holding)
  • GlaxoSmithKline

Representative Publications
Lanasa MC, Allgood SD, Slager SL, Dave SS, Love C, Marti GE, Kay NE, Hanson CA, Rabe KG, Achenbach SJ, Goldin LR, Camp NJ, Goodman BK, Vachon CM, Spector LG, Rassenti LZ, Leis JF, Gockerman JP, Strom SS, Call TG, Glenn M, Cerhan JR, Levesque MC, Weinberg JB, Caporaso NE. Immnuophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. Leukemia. 2011 May 27. (2011) Abstract

Lanasa MC, Weinberg JB. Immunoglobulin class switch recombination in chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Jul;52(7):1398-400. (2011) Abstract

Lanasa MC, Weinberg JB. Immunologic aspects of monoclonal B-cell lymphocytosis. Immunol Res. 2011 Apr;49(1-3):269-80. (2011) Abstract

Slager SL, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti LZ, Leis JF, Camp NJ, Glenn M, Kay NE, Cunningham JM, Hanson CA, Marti GE, Weinberg JB, Morrison VA, Link BK, Call TG, Caporaso NE, Cerhan JR. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2011 Feb 10;117(6):1911-6. (2011) Abstract

Goldin LR, Lanasa MC, Slager SL, Cerhan JR, Vachon CM, Strom SS, Camp NJ, Spector LG, Leis JF, Morrison VA, Glenn M, Rabe KG, Achenbach SJ, Algood SD, Abbasi F, Fontaine L, Yau M, Rassenti LZ, Kay NE, Call TG, Hanson CA, Weinberg JB, Marti GE, Caporaso NE. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol. 2010 Oct;151(2):152-8. (2010) Abstract

Lanasa MC, Allgood SD, Volkheimer AD, Gockerman JP, Whitesides JF, Goodman BK, Moore JO, Weinberg JB, Levesque MC. Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. Leukemia. 2010 Jan;24(1):133-40. (2010) Abstract

Lanasa MC. Novel insights into the biology of CLL. Hematology Am Soc Hematol Educ Program. 2010;2010:70-6. (2010) Abstract

Rawstron AC, Shanafelt T, Lanasa MC, Landgren O, Hanson C, Orfao A, Hillmen P, Ghia P. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom. 2010;78 Suppl 1:S19-23. (2010) Abstract

Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010 Mar;24(3):512-20. (2010) Abstract

Slager SL, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti L, Leis JF, Camp NJ, Kay NE, Vachon CM, Glenn M, Weinberg JB, Rabe KG, Cunningham JM, Achenbach SJ, Hanson CA, Marti GE, Call TG, Caporaso NE, Cerhan JR. Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1098-102. (2010) Abstract

Lanasa MC, Allgood SD, Bond KM, Gockerman JP, Levesque MC, Weinberg JB. Oligoclonal TRBV gene usage among CD8(+) T cells in monoclonal B lymphocytosis and CLL. Br J Haematol. 2009 May;145(4):535-7. (2009) Abstract

Weinberg JB, Volkheimer AD, Chen Y, Beasley BE, Jiang N, Lanasa MC, Friedman D, Vaccaro G, Rehder CW, Decastro CM, Rizzieri DA, Diehl LF, Gockerman JP, Moore JO, Goodman BK, Levesque MC. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol. 2007 Dec;82(12):1063-70. (2007) Abstract

Contact Us | Careers | Privacy Policy | Make a Gift | Site Map | RSS Feeds | En EspaƱol | Mobile Site | Help
Duke Medicine | Duke School of Medicine | Duke Children's | Duke University
Toll-Free: 888-ASK-DUKE (888-275-3853)
Copyright © 2004-2012 Duke University Health System

About This Page

Updated: July 25, 2008
Published: July 25, 2008
URL: http://www.dukehealth.org/physicians/mark_c_lanasa